Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The two groups showed no remarkable differences in terms of baseline demographics, nutritional parameters (energy and protein), and metabolic indicators (fasting glucose, total cholesterol, and vitamin D).

Source: 3.1. Comparison of Baseline Characteristics Between the Non-Sarcopenia and Sarcopenia Groups. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Based on the World Health Organization (WHO) guidelines on physical activity for health, participants were classified as meeting recommendations if they engaged in ≥150 min per week of moderate-intensity activity or ≥75 min per week of vigorous-intensity activity [].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Male Sex and Obesity are Associated with Sarcopenia in Patients with Rheumatoid Arthritis in the 2008 to 2011 Korea National Health and Nutrition Examination Survey

Study design awaiting verification · Journal of Clinical Medicine · 2026

Original publication title

Male Sex and Obesity are Associated with Sarcopenia in Patients with Rheumatoid Arthritis in the 2008 to 2011 Korea National Health and Nutrition Examination Survey

Yoon-Jeong Oh; Chang-Nam Son

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In conclusion, our findings emphasize the substantial burden of sarcopenia among patients with RA, and identify male sex and obesity as important risk factors. Clinicians should consider routine assessments of muscle mass and function in RA management, especially in high-risk individuals. Future research using longitudinal data is warranted to clarify the causal mechanisms and evaluate interventions aimed at preventing sarcopenia in this patient population.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Rheumatoid arthritis (RA) is a systemic, immune-mediated disorder characterized by chronic inflammation of the joints, leading to persistent synovitis, pain, and progressive joint destruction [1]. In addition to joint involvement, RA often leads to various systemic complications, such as fatigue, cardiovascular disease, and sarcopenia, all of which substantially impair functional ability and overall quality of life [2]. Chronic systemic inflammation in RA is a key mechanism that drives both musculoskeletal decline and cardiovascular risk [3].

Specifically, this persistent inflammatory state accelerates atherosclerosis and disrupts the balance of oxygen supply to the heart, which is central to the development of Type 2 myocardial infarction (T2MI) [4]. This highlights that RA should be managed as a complex systemic disorder with broad impact on multiple organs, rather than just a localized joint disease.

Sarcopenia is defined by a progressive reduction in skeletal muscle mass, muscle power, and physical performance [5]. Although sarcopenia is commonly associated with aging, it can develop secondary to chronic conditions, including RA, malignancy, or chronic systemic diseases, affecting the kidneys, liver, heart, or lungs [6,7]. Several studies suggest that although sarcopenia affects 5 to 13% of the general population aged 60 to 70 years, its prevalence in patients with RA may be >25% [8,9].

The high prevalence of sarcopenia in this population is associated with reduced physical activity due to pain and sustained systemic inflammation [5,10]. Proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6, accelerate muscle catabolism and impair repair mechanisms, resulting in a more rapid muscle loss than occurs with aging alone [10,11]. These inflammatory pathways may also interact with metabolic processes such as insulin resistance and adipokine dysregulation, further worsening clinical outcomes and potentially promoting sarcopenic obesity [12].

Consequently, patients with both RA and sarcopenia are at increased risk of physical disability, falls, fractures, and mortality, imposing a substantial burden on healthcare systems [10,13].

Recent observations indicate that muscle loss in RA does not follow a single pattern but is instead influenced by complex factors, including sex and obesity [14,15]. The interaction between hormonal regulation, adiposity, and inflammation may lead to distinct clinical outcomes between men and women. However, comprehensive studies are still needed to better understand how these factors contribute to RA-associated sarcopenia. In particular, despite its clinical significance, large-scale, population-based studies using standardized, weight-adjusted appendicular skeletal muscle mass (ASM) criteria validated in the Korean population are lacking.

Most previous studies used small clinical cohorts or inconsistent definitions of sarcopenia, limiting the comparability and generalizability of their findings [5,16].

Therefore, this study sought to investigate the prevalence and determinants of sarcopenia among Korean adults with RA, based on data from the Korea National Health and Nutrition Examination Survey (KNHANES). We specifically examined how sex and body composition relate to sarcopenia risk. This focus may provide practical insights into the clinical burden of sarcopenia in patients with RA. A better understanding of these relationships may help clinicians identify high-risk individuals and develop targeted strategies to prevent and manage sarcopenia in this population.

Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Data Source and Study Design

This study utilized data from the 2008 to 2011 cycles of the KNHANES, a nationally representative survey conducted to assess the health and nutritional status of the Korean population [17]. Among 16,378 participants, 238 adults (≥19 years) with RA were included in the analysis. RA was defined as self-reported physician-diagnosed RA or current treatment for RA based on the KNHANES health interview. In KNHANES, disease status is assessed through standardized health interviews, in which participants are asked whether they have ever been diagnosed with RA by a physician or are currently receiving treatment for RA.

This study was approved by the Institutional Review Board of the Uijeongbu Eulji Medical Center (UEMC 2025-08-002-001), and conducted in accordance with the Declaration of Helsinki.

2.2. Definition of Sarcopenia and BMI Categories

In the KNHANES, ASM was assessed via dual-energy X-ray absorptiometry (QDR 4500A; Hologic Inc., Bedford, MA, USA) [18]. ASM was defined as the sum of lean soft tissue mass in the upper and lower extremities, excluding fat and bone components, and is considered a surrogate measure of skeletal muscle mass [19]. Sarcopenia was operationally defined using weight-adjusted ASM (ASM/weight × 100), which accounts for differences in body size and composition. Sex-specific cut-off values (<29% for men and <22.9% for women) were applied based on Korean population reference data [9,20].

This definition has been widely applied in previous KNHANES-based epidemiological studies and is considered appropriate for reflecting body composition in Asian populations [21,22,23]. Body mass index (BMI) was categorized based on the Korean Society for the Study of Obesity recommendations and divided into the following categories: underweight (<18.5 kg/m2), normal weight (18.5 to 22.9 kg/m2), overweight (23.0 to 24.9 kg/m2), and obese (≥25.0 kg/m2) [24].

2.3. Health and Dietary Behavioral Characteristics

Health-related behaviors and clinical variables were assessed using standardized protocols from the KNHANES health interview and examination surveys conducted between 2008 and 2011. Information on health-related behaviors (e.g., smoking, alcohol consumption, and physical activity) was collected via standardized self-reported questionnaires administered by trained interviewers, while clinical measurements (e.g., blood pressure, laboratory values, and physical characteristics of the participants) were obtained through direct physical examinations and laboratory analyses. Alcohol consumption was defined as drinking at least once a month over the past year.

Current smoking status was defined as smoking daily or occasionally during the survey. Physical activity was assessed using the Korean version of the International Physical Activity Questionnaire short form. Based on the World Health Organization (WHO) guidelines on physical activity for health, participants were classified as meeting recommendations if they engaged in ≥150 min per week of moderate-intensity activity or ≥75 min per week of vigorous-intensity activity [25]. Those who did not meet these criteria were categorized into the physically inactive group.

Hypertension (HTN) was identified based on a systolic blood pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90 mmHg. Additionally, participants with a documented physician diagnosis or those undergoing antihypertensive therapy were also included in this category. Diabetes mellitus (DM) was defined as a fasting plasma glucose level ≥ 126 mg/dL, a physician diagnosis, or current treatment for diabetes. Hyperlipidemia was defined as a fasting total cholesterol level ≥ 240 mg/dL, a physician diagnosis, or current use of lipid-lowering medications.

Only participants who had fasted for at least 8 h prior to blood sampling were included for the laboratory-based definition to improve data accuracy. Osteoarthritis (OA) and depression were defined based on physician diagnosis, current treatment, or current disease status. Osteoporosis was defined according to bone mineral density measurements, with a T-score ≤ −2.5 at the total femur, femoral neck, or lumbar spine. We assessed health-related quality of life using the EuroQol-5 Dimension (EQ-5D) index, a standardized tool that encompasses five dimensions [26].

These domains include physical mobility and self-care, as well as the performance of daily activities, the presence of pain or discomfort, and mental health status regarding anxiety or depression [26]. The resulting index score ranges from 0 to 1, with higher values indicating a better health status. We used the Korean-specific valuation set to calculate the final index score [27].

2.4. Statistical Analysis

All statistical analyses were performed using SPSS version 23.0, accounting for the complex survey design of the KNHANES by incorporating sampling weights, strata, and clusters. The resulting weighted estimates are representative of the Korean population and reflect population-level values rather than raw sample data. Continuous variables are expressed as weighted means with 95% confidence intervals (CIs), while categorical variables are presented as weighted proportions. Group comparisons were performed using the complex samples general linear model and the Rao: Scott adjusted chi-square test.

Independent factors associated with sarcopenia were examined using multivariate logistic regression analyses, with variables selected based on clinical relevance and univariate significance. This model further evaluated the association of sex and BMI, adjusting for age and other potential confounders. The results are presented as adjusted odds ratios (ORs) with 95% CIs. Weighted proportions and their 95% CIs were calculated using the Taylor series linearization method within the complex samples module of SPSS. All statistical tests were two-tailed, and a p-value < 0.05 was considered statistically significant.

Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods

Comparison of Baseline Characteristics Between the Non-Sarcopenia and Sarcopenia Groups

Results: Comparison of Baseline Characteristics Between the Non-Sarcopenia and Sarcopenia Groups

A total of 238 patients with RA were included in the analysis, of whom 44 (weighted prevalence, 22.7%) were classified as having sarcopenia. Table 1 summarizes the baseline characteristics of the study population according to sarcopenia status. Compared with individuals without sarcopenia, those with sarcopenia were more likely to be male (55.0% vs. 15.3%, p < 0.001) and had significantly higher BMI (26.1 vs. 23.3 kg/m2, p < 0.001) as well as greater waist circumference (86.9 vs. 79.0 cm, p < 0.001).

The prevalence of obesity was also significantly higher among individuals with sarcopenia (54.1% vs. 25.9%, p = 0.003). The two groups showed no remarkable differences in terms of baseline demographics, nutritional parameters (energy and protein), and metabolic indicators (fasting glucose, total cholesterol, and vitamin D). Furthermore, the distribution of comorbidities, such as HTN, hyperlipidemia, OA, osteoporosis, and depression, was comparable between the two groups. Although not statistically significant, a lower proportion of individuals with sarcopenia met the WHO physical activity guidelines compared with those without sarcopenia (73.5% vs. 88.1%, p = 0.070).

Table 1

Baseline characteristics of study participants according to sarcopenia status.

VariablesNon-Sarcopenia (n = 194)Sarcopenia (n = 44)p Value
Age, years56.0 (53.4 to 58.6)52.2 (45.4 to 59.0)0.279
Male, %15.3 (9.7 to 23.2)55.0 (37.0 to 71.8)<0.001
BMI, kg/m223.3 (22.8 to 23.8)26.1 (24.9 to 27.2)<0.001
Waist circumference (cm)79.0 (77.5 to 80.5)86.9 (84.2 to 89.6)<0.001
Current smoker, %60.6 (43.5 to 75.5)66.2 (45.8 to 82.0)0.662
Current drinker, %39.0 (30.7 to 48.0)51.9 (33.7 to 69.6)0.212
Obesity, %25.9 (19.6 to 33.3)54.1 (35.9 to 71.2)0.003
Meets WHO physical activity guideline88.1 (81.3 to 92.7)73.5 (51.5 to 87.8)0.070
EQ-5D index0.9 (0.8 to 0.9)0.8 (0.7 to 0.9)0.448
Intake energy, g/day1665.8 (1524.5 to 1807.0)1642.4 (1408.7 to 1876.2)0.868
Protein, g/kg/day57.7 (51.4 to 64.1)58.5 (45.7 to 71.3)0.920
Fasting glucose96.3 (91.5 to 101.2)106.2 (86.8 to 125.6)0.337
Total cholesterol189.0 (183.5 to 194.6)189.5 (173.4 to 205.6)0.958
25 (OH) Vitamin D18.5 (16.8 to 20.2)17.3 (15.1 to 19.6)0.401
Comorbidities, %
Hypertension28.0 (21.4 to 35.8)24.3 (11.7 to 43.8)0.680
Hyperlipidemia14.1 (9.5 to 20.5)20.2 (8.5 to 40.7)0.428
Osteoarthritis23.4 (16.6 to 31.8)13.4 (5.5 to 29.1)0.161
Osteoporosis36.6 (28.6 to 45.5)21.9 (9.9 to 41.8)0.131
MDD15.7 (10.2 to 23.4)14.3 (5.2 to 33.6)0.833

Values are presented as weighted means (95% confidence intervals) for continuous variables and as weighted percentages (95% confidence intervals) for categorical variables. p-values were calculated using a complex sample general linear model, accounting for sample weights, strata, and clusters. n represents an unweighted sample. All estimates are weighted to represent the Korean population. WHO, World Health Organization; MDD, major depressive disorder; EQ-5D, EuroQol-5-Dimension.

Source: 3.1. Comparison of Baseline Characteristics Between the Non-Sarcopenia and Sarcopenia Groups Source: 3.1. Comparison of Baseline Characteristics Between the Non-Sarcopenia and Sarcopenia Groups

Clinical Predictors of Sarcopenia in Patients with RA

Results: Clinical Predictors of Sarcopenia in Patients with RA

Univariate analyses demonstrated that male sex (OR: 6.79; 95% CI: 2.76 to 16.67, p < 0.001) and obesity (OR: 3.37; 95% CI: 1.51 to 7.53, p = 0.003) were significantly associated with the presence of sarcopenia (Table 2). After adjusting for age, obesity, physical activity, and protein intake, both male sex (OR: 4.17; 95% CI: 1.48 to 11.77, p = 0.007) and obesity (OR: 3.06; 95% CI: 1.16 to 8.07, p = 0.024) persisted as independent predictors of sarcopenia. Meeting the WHO physical activity guideline showed a trend towards association (OR: 0.39; 95% CI: 0.14 to 1.06, p = 0.064), but did not demonstrate a significant effect.

Neither age nor daily protein intake reached statistical significance regarding sarcopenia risk in either the univariate or multivariable analyses.

Table 2

Logistic regression analysis of factors associated with sarcopenia in patients with RA.

VariablesUnivariateMultivariate
OR (95% CI)p ValueOR (95% CI)p Value
Male6.79 (2.76 to 16.67)<0.0014.17 (1.48 to 11.77)0.007
Age0.98 (0.96 to 1.01)0.2561.00 (0.96 to 1.03)0.781
Obesity3.37 (1.51 to 7.53)0.0033.06 (1.16 to 8.07)0.024
Meets WHO physical activity guideline0.37 (0.13 to 1.12)0.0780.39 (0.14 to 1.06)0.064
Daily protein intake1.00 (0.99 to 1.01)0.9191.00 (0.98 to 1.01)0.597

Values are presented as weighted odds ratios (ORs) with 95% confidence intervals (CIs) for univariate and multivariate logistic regression models. Multivariate analysis included adjustments for age, sex, obesity, physical activity, and daily protein intake, along with sample weights, strata, and clusters based on a complex survey design. WHO, World Health Organization.

Source: 3.2. Clinical Predictors of Sarcopenia in Patients with RA Source: 3.2. Clinical Predictors of Sarcopenia in Patients with RA

Sarcopenia Prevalence and Risk According to BMI Category

Results: Sarcopenia Prevalence and Risk According to BMI Category

Sarcopenia prevalence demonstrated a stepwise increase across BMI categories, rising from 10.1% in the underweight and normal BMI group (<18.5 and 18.5 to 22.9 kg/m2) to 28.0% in the overweight group (23.0 to 24.9 kg/m2) and further to 44.9% in the obese group (≥25.0 kg/m2) (Figure 1). In the multivariable logistic regression analysis adjusted for age and sex, the odds of sarcopenia were significantly higher in overweight (OR: 3.07; 95% CI: 1.02 to 9.22, p < 0.001) and obese (OR: 6.11; 95% CI: 2.06 to 18.12, p < 0.001) groups compared with the underweight and normal BMI group as the reference (Table 3).

These findings support a dose: response association between increasing BMI and the likelihood of sarcopenia.

Table 3

Sarcopenia prevalence and odds ratios according to BMI category in patients with RA.

BMI Category (kg/m2)Weighted NWeighted Sarcopenia NWeighted Prevalence (%) OR
(95% CI)
p Value
Underweight and Normal BMI
(<18.5 and 18.5 to 22.9, respectively)
48,964,6414,929,49910.11.00 (Reference)
Overweight
(23.0 to 24.9)
18,109,7205,072,29528.03.07 (1.02 to 9.22)<0.001
Obese (≥25.0)24,395,84010,947,70444.96.11 (2.06 to 18.12)<0.001

N and the percentages are weighted estimates that account for the complex survey design. BMI, body mass index; OR, odds ratio; CI, confidence interval. Weighted proportions may not sum to 100% due to rounding and the application of sampling weights. p-values were calculated using the underweight and normal BMI group as the reference.

Source: 3.3. Sarcopenia Prevalence and Risk According to BMI Category Source: 3.3. Sarcopenia Prevalence and Risk According to BMI Category

Sex-Specific Multivariable Analysis of Risk Factors for Sarcopenia

Results: Sex-Specific Multivariable Analysis of Risk Factors for Sarcopenia

Sex-stratified multivariable analyses were conducted to examine potential differences in factors associated with sarcopenia between male and female participants (Table 4). In the male patients, not meeting the WHO physical activity guideline was markedly linked to a heightened risk of sarcopenia (OR: 13.00; 95% CI: 1.90 to 88.75, p = 0.012). Additionally, BMI was positively associated with sarcopenia in males (OR: 1.33; 95% CI: 1.05 to 1.68, p = 0.022), although age was not significantly related to sarcopenia (OR: 1.03; 95% CI: 0.99 to 1.08, p = 0.127).

In contrast, among the female patients, only BMI was significantly associated with sarcopenia (OR: 1.35; 95% CI: 1.14 to 1.61, p = 0.001). Age and physical activity did not reach statistical significance in the female group (all p > 0.05). These results suggest that physical activity may influence the risk of sarcopenia differently by sex, although this finding should be interpreted with caution. Due to the limited number of participants in the sex-stratified analyses, particularly among men with sarcopenia, the estimates were associated with wide CIs.

Table 4

Multivariable logistic regression analysis of factors associated with sarcopenia in male and female patients with RA.

VariablesMale OR (95% CI), pFemale OR (95% CI), p
Age1.03 (0.99 to 1.08), p = 0.1271.00 (0.96 to 1.03), p = 0.786
BMI1.33 (1.05 to 1.68), p = 0.0221.35 (1.14 to 1.61), p = 0.001
Not meeting WHO physical activity guideline13.00 (1.90 to 88.75), p = 0.0120.59 (0.12 to 3.01), p = 0.520

Values are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Separate multivariate logistic regression models were fitted for male and female patients, adjusting for age, body mass index (BMI), and adherence to the World Health Organization (WHO) physical activity guidelines. The analyses used a complex survey design that included sampling weights, strata, and clusters. The number of participants included in the sex-stratified analyses was 45 for men (18 with sarcopenia and 27 without) and 193 for women (26 with sarcopenia and 167 without).

Source: 3.4. Sex-Specific Multivariable Analysis of Risk Factors for Sarcopenia Source: 3.4. Sex-Specific Multivariable Analysis of Risk Factors for Sarcopenia

Discussion

In this nationally representative cohort from the KNHANES, the weighted prevalence of sarcopenia in patients with RA was about 22.7%. This prevalence is substantially higher than that reported in the general Korean population and underscores the clinical burden of sarcopenia in individuals with RA [28]. Furthermore, our multivariable analyses identified male sex (OR: 4.17; 95% CI: 1.48 to 11.77) and obesity (OR: 3.06; 95% CI: 1.16 to 8.07) as independent risk factors for sarcopenia. The current findings support previous evidence that sarcopenia in RA is associated with sex and obesity [9,29].

In sex-stratified analyses, physical inactivity was significantly associated with sarcopenia only in male patients, whereas BMI remained a significant risk factor in both sexes. Our observations underscore the complex interaction between sex, body composition, and physical activity in RA-related sarcopenia. Furthermore, they underscore the clinical significance of this comorbidity, warranting individualized evaluation and management approaches in susceptible groups.

Several pathophysiological mechanisms can explain the association between RA and sarcopenia. Sarcopenia is a multifactorial condition involving age-related anabolic resistance, chronic inflammation, hormonal changes, physical inactivity, inadequate nutrition, and neuromuscular degeneration [30]. In patients with RA, the persistent release of systemic inflammatory mediators, such as TNF-α, IL-6, and IL-1β, disrupts muscle protein regulation by inhibiting protein synthesis via the insulin-like growth factor-1 (IGF-1)/Akt/mTOR signaling pathway and promoting proteolysis through the ubiquitin: proteasome system [10,31]. Additionally, chronic inflammation causes pain, joint stiffness, and fatigue, which collectively limit physical activity, exacerbate muscle atrophy, and contribute to functional decline [32].

These findings support the central role of inflammation-related molecular and behavioral mechanisms in the pathogenesis of sarcopenia in patients with RA [33]. Moreover, long-term use of glucocorticoids, which are frequently prescribed for the management of RA, may contribute to muscle wasting by increasing protein breakdown and impairing myogenesis. A previous study reported that glucocorticoid use was markedly associated with a higher likelihood of sarcopenia in patients with RA [29]. Therefore, these RA-specific factors establish a chronic catabolic state that promotes the development of sarcopenia.

These mechanisms may partially explain why male sex and excess weight are independently associated with sarcopenia in our analysis. While age-related declines in anabolic hormones like testosterone contribute to muscle loss, male patients in this study showed a significantly higher vulnerability to sarcopenia. This is notable because post-menopausal women experience a more rapid loss of estrogen, suggesting that sex-specific differences in RA involve factors beyond hormonal changes alone. Given that men generally have a greater baseline muscle mass, the catabolic effects of RA-associated chronic inflammation may result in muscle wasting that is more clinically significant than in women.

A previous study also reported that age-related muscle loss progressed more rapidly in men than in women [34,35]. Furthermore, the regulation of muscle protein in response to inflammation differs by sex. Specifically, it has been suggested that the IGF-1/Akt/mTOR axis in men may be more susceptible to inhibition by inflammatory cytokines [36]. In addition to these biological factors, our analysis revealed that physical inactivity was significantly associated with sarcopenia only in male patients. This suggests that lifestyle adjustments in response to RA symptoms, specifically regarding physical activity, may play a critical role in maintaining muscle mass in an inflammatory state.

Thus, the higher prevalence of sarcopenia in men likely results from a combination of greater absolute muscle loss, a higher biological sensitivity to inflammation, and a stronger link between physical inactivity and muscle depletion. These findings suggest that sex-specific hormonal and inflammatory profiles may significantly influence susceptibility to sarcopenia in patients with RA.

Data from this research demonstrated that the prevalence of sarcopenia increased progressively with BMI category, reaching 44.9% among patients with obesity, which suggests a dose: response relationship between increasing adiposity and the risk of muscle loss. While higher body weight is traditionally viewed as a protective mechanical load [37], our findings align with recent clinical observations identifying obesity as an independent risk factor for muscle depletion in RA [28,29]. This clinical discrepancy can be explained by the concept of sarcopenic obesity, which is characterized by the coexistence of excessive adiposity and reduced muscle mass [38].

In this condition, adipose tissue-derived proinflammatory adipokines, such as leptin and IL-6, impair muscle metabolism, while obesity-induced insulin resistance disrupts the anabolic signaling required for muscle protein synthesis [39]. Additionally, obesity-related physical limitations may further reduce the physical activity levels of patients with RA, thereby accelerating muscle loss. This issue is especially critical in Asian populations, including Korean cohorts [40,41]. These individuals often have a lower baseline of muscle mass, which makes them more vulnerable to sarcopenic obesity even at a relatively lower BMI.

Thus, the concurrence of obesity and sarcopenia in RA patients is a critical clinical factor that can significantly worsen disease progression rather than it being a simple coincidence, as reduced muscle mass in these patients can severely impair physical function and increase disability while being masked by excess adiposity. This overlap makes disease management more difficult, as weight-based assessments frequently underestimate the severity of muscle loss. Consequently, identifying sarcopenic obesity in patients with RA may be important for optimizing treatment strategies, including targeted nutritional support and tailored exercise interventions.

Our findings ultimately highlight the need for routine assessments of muscle mass and function in patients with RA, especially among men and those with obesity.

Beyond physical disability, the clinical importance of sarcopenic obesity in RA is closely linked to cardiometabolic comorbidities. The synergistic effect of adiposity and systemic inflammation not only reduces muscle mass but also promotes endothelial dysfunction and cardiovascular disease risk [3]. Sex-specific inflammatory responses further contribute to the cardiovascular risks associated with sarcopenic obesity. For instance, recent research on T2MI reveals that women may be more susceptible to a high inflammatory burden, as it is driven by an imbalance in myocardial oxygen supply and demand rather than acute plaque rupture [4].

Although our findings emphasize the high risk of sarcopenia in men, these observations suggest that the interaction between sex and inflammation in RA affects musculoskeletal and cardiovascular health in distinct ways. Consequently, our results underscore the importance of a comprehensive risk assessment that considers both body composition and sex-specific cardiovascular risks in patients with RA.

The present study has several limitations. First, due to its cross-sectional design, causality between the observed risk factors and sarcopenia cannot be determined. Second, RA diagnoses and comorbidities were based on self-reported physician diagnoses or current treatment status, which may be subject to recall bias. Moreover, although related musculoskeletal conditions (such as OA) are assessed separately in the KNHANES, some degree of misclassification cannot be completely ruled out, potentially influencing the estimated prevalence of sarcopenia. Third, physical activity was assessed using self-reported questionnaires rather than objective measures, which may have affected its accuracy.

Furthermore, a key limitation of this study is the lack of detailed RA-specific clinical variables, such as disease activity, disease duration, serological markers, functional status, and information on pharmacological treatments. These factors are known to influence muscle mass and may contribute to the development of sarcopenia in patients with RA. Therefore, residual confounding cannot be excluded, and the observed associations should be interpreted with caution. Additionally, the sex-stratified analyses are limited by a constrained sample size, particularly men with sarcopenia (n = 18), which may have reduced statistical power and resulted in wide confidence intervals.

Consequently, these findings should be interpreted as preliminary rather than definitive. Future studies incorporating detailed clinical data are needed to better elucidate these relationships. However, an important strength of this study is the use of a large, nationally representative dataset to examine weight-adjusted ASM criteria for sarcopenia in the Korean population.

Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion

Results

3.1. Comparison of Baseline Characteristics Between the Non-Sarcopenia and Sarcopenia Groups

A total of 238 patients with RA were included in the analysis, of whom 44 (weighted prevalence, 22.7%) were classified as having sarcopenia. Table 1 summarizes the baseline characteristics of the study population according to sarcopenia status. Compared with individuals without sarcopenia, those with sarcopenia were more likely to be male (55.0% vs. 15.3%, p < 0.001) and had significantly higher BMI (26.1 vs. 23.3 kg/m2, p < 0.001) as well as greater waist circumference (86.9 vs. 79.0 cm, p < 0.001).

The prevalence of obesity was also significantly higher among individuals with sarcopenia (54.1% vs. 25.9%, p = 0.003). The two groups showed no remarkable differences in terms of baseline demographics, nutritional parameters (energy and protein), and metabolic indicators (fasting glucose, total cholesterol, and vitamin D). Furthermore, the distribution of comorbidities, such as HTN, hyperlipidemia, OA, osteoporosis, and depression, was comparable between the two groups. Although not statistically significant, a lower proportion of individuals with sarcopenia met the WHO physical activity guidelines compared with those without sarcopenia (73.5% vs. 88.1%, p = 0.070).

3.2. Clinical Predictors of Sarcopenia in Patients with RA

Univariate analyses demonstrated that male sex (OR: 6.79; 95% CI: 2.76 to 16.67, p < 0.001) and obesity (OR: 3.37; 95% CI: 1.51 to 7.53, p = 0.003) were significantly associated with the presence of sarcopenia (Table 2). After adjusting for age, obesity, physical activity, and protein intake, both male sex (OR: 4.17; 95% CI: 1.48 to 11.77, p = 0.007) and obesity (OR: 3.06; 95% CI: 1.16 to 8.07, p = 0.024) persisted as independent predictors of sarcopenia. Meeting the WHO physical activity guideline showed a trend towards association (OR: 0.39; 95% CI: 0.14 to 1.06, p = 0.064), but did not demonstrate a significant effect.

Neither age nor daily protein intake reached statistical significance regarding sarcopenia risk in either the univariate or multivariable analyses.

3.3. Sarcopenia Prevalence and Risk According to BMI Category

Sarcopenia prevalence demonstrated a stepwise increase across BMI categories, rising from 10.1% in the underweight and normal BMI group (<18.5 and 18.5 to 22.9 kg/m2) to 28.0% in the overweight group (23.0 to 24.9 kg/m2) and further to 44.9% in the obese group (≥25.0 kg/m2) (Figure 1). In the multivariable logistic regression analysis adjusted for age and sex, the odds of sarcopenia were significantly higher in overweight (OR: 3.07; 95% CI: 1.02 to 9.22, p < 0.001) and obese (OR: 6.11; 95% CI: 2.06 to 18.12, p < 0.001) groups compared with the underweight and normal BMI group as the reference (Table 3).

These findings support a dose: response association between increasing BMI and the likelihood of sarcopenia.

3.4. Sex-Specific Multivariable Analysis of Risk Factors for Sarcopenia

Sex-stratified multivariable analyses were conducted to examine potential differences in factors associated with sarcopenia between male and female participants (Table 4). In the male patients, not meeting the WHO physical activity guideline was markedly linked to a heightened risk of sarcopenia (OR: 13.00; 95% CI: 1.90 to 88.75, p = 0.012). Additionally, BMI was positively associated with sarcopenia in males (OR: 1.33; 95% CI: 1.05 to 1.68, p = 0.022), although age was not significantly related to sarcopenia (OR: 1.03; 95% CI: 0.99 to 1.08, p = 0.127).

In contrast, among the female patients, only BMI was significantly associated with sarcopenia (OR: 1.35; 95% CI: 1.14 to 1.61, p = 0.001). Age and physical activity did not reach statistical significance in the female group (all p > 0.05). These results suggest that physical activity may influence the risk of sarcopenia differently by sex, although this finding should be interpreted with caution. Due to the limited number of participants in the sex-stratified analyses, particularly among men with sarcopenia, the estimates were associated with wide CIs.

Table 1

Baseline characteristics of study participants according to sarcopenia status.

VariablesNon-Sarcopenia (n = 194)Sarcopenia (n = 44)p Value
Age, years56.0 (53.4 to 58.6)52.2 (45.4 to 59.0)0.279
Male, %15.3 (9.7 to 23.2)55.0 (37.0 to 71.8)<0.001
BMI, kg/m223.3 (22.8 to 23.8)26.1 (24.9 to 27.2)<0.001
Waist circumference (cm)79.0 (77.5 to 80.5)86.9 (84.2 to 89.6)<0.001
Current smoker, %60.6 (43.5 to 75.5)66.2 (45.8 to 82.0)0.662
Current drinker, %39.0 (30.7 to 48.0)51.9 (33.7 to 69.6)0.212
Obesity, %25.9 (19.6 to 33.3)54.1 (35.9 to 71.2)0.003
Meets WHO physical activity guideline88.1 (81.3 to 92.7)73.5 (51.5 to 87.8)0.070
EQ-5D index0.9 (0.8 to 0.9)0.8 (0.7 to 0.9)0.448
Intake energy, g/day1665.8 (1524.5 to 1807.0)1642.4 (1408.7 to 1876.2)0.868
Protein, g/kg/day57.7 (51.4 to 64.1)58.5 (45.7 to 71.3)0.920
Fasting glucose96.3 (91.5 to 101.2)106.2 (86.8 to 125.6)0.337
Total cholesterol189.0 (183.5 to 194.6)189.5 (173.4 to 205.6)0.958
25 (OH) Vitamin D18.5 (16.8 to 20.2)17.3 (15.1 to 19.6)0.401
Comorbidities, %
Hypertension28.0 (21.4 to 35.8)24.3 (11.7 to 43.8)0.680
Hyperlipidemia14.1 (9.5 to 20.5)20.2 (8.5 to 40.7)0.428
Osteoarthritis23.4 (16.6 to 31.8)13.4 (5.5 to 29.1)0.161
Osteoporosis36.6 (28.6 to 45.5)21.9 (9.9 to 41.8)0.131
MDD15.7 (10.2 to 23.4)14.3 (5.2 to 33.6)0.833

Values are presented as weighted means (95% confidence intervals) for continuous variables and as weighted percentages (95% confidence intervals) for categorical variables. p-values were calculated using a complex sample general linear model, accounting for sample weights, strata, and clusters. n represents an unweighted sample. All estimates are weighted to represent the Korean population. WHO, World Health Organization; MDD, major depressive disorder; EQ-5D, EuroQol-5-Dimension.

Table 2

Logistic regression analysis of factors associated with sarcopenia in patients with RA.

VariablesUnivariateMultivariate
OR (95% CI)p ValueOR (95% CI)p Value
Male6.79 (2.76 to 16.67)<0.0014.17 (1.48 to 11.77)0.007
Age0.98 (0.96 to 1.01)0.2561.00 (0.96 to 1.03)0.781
Obesity3.37 (1.51 to 7.53)0.0033.06 (1.16 to 8.07)0.024
Meets WHO physical activity guideline0.37 (0.13 to 1.12)0.0780.39 (0.14 to 1.06)0.064
Daily protein intake1.00 (0.99 to 1.01)0.9191.00 (0.98 to 1.01)0.597

Values are presented as weighted odds ratios (ORs) with 95% confidence intervals (CIs) for univariate and multivariate logistic regression models. Multivariate analysis included adjustments for age, sex, obesity, physical activity, and daily protein intake, along with sample weights, strata, and clusters based on a complex survey design. WHO, World Health Organization.

Table 3

Sarcopenia prevalence and odds ratios according to BMI category in patients with RA.

BMI Category (kg/m2)Weighted NWeighted Sarcopenia NWeighted Prevalence (%) OR
(95% CI)
p Value
Underweight and Normal BMI
(<18.5 and 18.5 to 22.9, respectively)
48,964,6414,929,49910.11.00 (Reference)
Overweight
(23.0 to 24.9)
18,109,7205,072,29528.03.07 (1.02 to 9.22)<0.001
Obese (≥25.0)24,395,84010,947,70444.96.11 (2.06 to 18.12)<0.001

N and the percentages are weighted estimates that account for the complex survey design. BMI, body mass index; OR, odds ratio; CI, confidence interval. Weighted proportions may not sum to 100% due to rounding and the application of sampling weights. p-values were calculated using the underweight and normal BMI group as the reference.

Table 4

Multivariable logistic regression analysis of factors associated with sarcopenia in male and female patients with RA.

VariablesMale OR (95% CI), pFemale OR (95% CI), p
Age1.03 (0.99 to 1.08), p = 0.1271.00 (0.96 to 1.03), p = 0.786
BMI1.33 (1.05 to 1.68), p = 0.0221.35 (1.14 to 1.61), p = 0.001
Not meeting WHO physical activity guideline13.00 (1.90 to 88.75), p = 0.0120.59 (0.12 to 3.01), p = 0.520

Values are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Separate multivariate logistic regression models were fitted for male and female patients, adjusting for age, body mass index (BMI), and adherence to the World Health Organization (WHO) physical activity guidelines. The analyses used a complex survey design that included sampling weights, strata, and clusters. The number of participants included in the sex-stratified analyses was 45 for men (18 with sarcopenia and 27 without) and 193 for women (26 with sarcopenia and 167 without).

Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results

Conclusions

In conclusion, our findings emphasize the substantial burden of sarcopenia among patients with RA, and identify male sex and obesity as important risk factors. Clinicians should consider routine assessments of muscle mass and function in RA management, especially in high-risk individuals. Future research using longitudinal data is warranted to clarify the causal mechanisms and evaluate interventions aimed at preventing sarcopenia in this patient population.

Source: 5. Conclusions
Authors’ abstract

Background/Objectives:

The objective of this investigation was to assess the prevalence of sarcopenia and identify its related risk factors in patients with rheumatoid arthritis (RA) using data from the nationally representative 2008 to 2011 Korea National Health and Nutrition Examination Survey (KNHANES).

Methods:

We analyzed data from the 2008 to 2011 KNHANES to identify the factors associated with sarcopenia in patients with RA. Sarcopenia was defined as the ratio of appendicular skeletal muscle mass to total body weight (multiplied by 100), with cut-offs of <29.0% for men and <22.9% for women. To identify the specific factors independently associated with sarcopenia, a multivariate logistic regression model was employed, accounting for sample weights and the complex survey design.

Results:

Among 238 patients with RA included in the analysis, 44 (weighted prevalence: 22.7%) had sarcopenia. The sarcopenia group had a higher proportion of males (55.0% vs. 15.3%, p < 0.001), body mass index (BMI) (26.1 vs. 23.3 kg/m2, p < 0.001), and waist circumference (86.9 vs. 79.0 cm, p < 0.001) than the non-sarcopenia group. After adjustment for potential confounders, including age, sex, obesity, physical activity, and daily protein intake, male sex (odds ratio [OR]: 4.17; 95% confidence interval [CI]: 1.48 to 11.77, p = 0.007) and obesity (OR: 3.06; 95% CI: 1.16 to 8.07, p = 0.024) were independently associated with sarcopenia. In sex-specific analyses, low physical activity was significantly associated with sarcopenia only in male patients (OR: 13.00; 95% CI: 1.90 to 88.75, p = 0.012).

Conclusions:

Our findings indicate that being male and having a higher BMI are significant independent indicators of sarcopenia risk within the Korean RA population. This highlights their critical role in the development of sarcopenia among RA patients.

Read the full paper

1. Introduction

Rheumatoid arthritis (RA) is a systemic, immune-mediated disorder characterized by chronic inflammation of the joints, leading to persistent synovitis, pain, and progressive joint destruction [1]. In addition to joint involvement, RA often leads to various systemic complications, such as fatigue, cardiovascular disease, and sarcopenia, all of which substantially impair functional ability and overall quality of life [2]. Chronic systemic inflammation in RA is a key mechanism that drives both musculoskeletal decline and cardiovascular risk [3].

Specifically, this persistent inflammatory state accelerates atherosclerosis and disrupts the balance of oxygen supply to the heart, which is central to the development of Type 2 myocardial infarction (T2MI) [4]. This highlights that RA should be managed as a complex systemic disorder with broad impact on multiple organs, rather than just a localized joint disease.

Sarcopenia is defined by a progressive reduction in skeletal muscle mass, muscle power, and physical performance [5]. Although sarcopenia is commonly associated with aging, it can develop secondary to chronic conditions, including RA, malignancy, or chronic systemic diseases, affecting the kidneys, liver, heart, or lungs [6,7]. Several studies suggest that although sarcopenia affects 5 to 13% of the general population aged 60 to 70 years, its prevalence in patients with RA may be >25% [8,9].

The high prevalence of sarcopenia in this population is associated with reduced physical activity due to pain and sustained systemic inflammation [5,10]. Proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6, accelerate muscle catabolism and impair repair mechanisms, resulting in a more rapid muscle loss than occurs with aging alone [10,11]. These inflammatory pathways may also interact with metabolic processes such as insulin resistance and adipokine dysregulation, further worsening clinical outcomes and potentially promoting sarcopenic obesity [12].

Consequently, patients with both RA and sarcopenia are at increased risk of physical disability, falls, fractures, and mortality, imposing a substantial burden on healthcare systems [10,13].

Recent observations indicate that muscle loss in RA does not follow a single pattern but is instead influenced by complex factors, including sex and obesity [14,15]. The interaction between hormonal regulation, adiposity, and inflammation may lead to distinct clinical outcomes between men and women. However, comprehensive studies are still needed to better understand how these factors contribute to RA-associated sarcopenia. In particular, despite its clinical significance, large-scale, population-based studies using standardized, weight-adjusted appendicular skeletal muscle mass (ASM) criteria validated in the Korean population are lacking.

Most previous studies used small clinical cohorts or inconsistent definitions of sarcopenia, limiting the comparability and generalizability of their findings [5,16].

Therefore, this study sought to investigate the prevalence and determinants of sarcopenia among Korean adults with RA, based on data from the Korea National Health and Nutrition Examination Survey (KNHANES). We specifically examined how sex and body composition relate to sarcopenia risk. This focus may provide practical insights into the clinical burden of sarcopenia in patients with RA. A better understanding of these relationships may help clinicians identify high-risk individuals and develop targeted strategies to prevent and manage sarcopenia in this population.

2. Materials and Methods

2.1. Data Source and Study Design

This study utilized data from the 2008 to 2011 cycles of the KNHANES, a nationally representative survey conducted to assess the health and nutritional status of the Korean population [17]. Among 16,378 participants, 238 adults (≥19 years) with RA were included in the analysis. RA was defined as self-reported physician-diagnosed RA or current treatment for RA based on the KNHANES health interview. In KNHANES, disease status is assessed through standardized health interviews, in which participants are asked whether they have ever been diagnosed with RA by a physician or are currently receiving treatment for RA.

This study was approved by the Institutional Review Board of the Uijeongbu Eulji Medical Center (UEMC 2025-08-002-001), and conducted in accordance with the Declaration of Helsinki.

2.2. Definition of Sarcopenia and BMI Categories

In the KNHANES, ASM was assessed via dual-energy X-ray absorptiometry (QDR 4500A; Hologic Inc., Bedford, MA, USA) [18]. ASM was defined as the sum of lean soft tissue mass in the upper and lower extremities, excluding fat and bone components, and is considered a surrogate measure of skeletal muscle mass [19]. Sarcopenia was operationally defined using weight-adjusted ASM (ASM/weight × 100), which accounts for differences in body size and composition. Sex-specific cut-off values (<29% for men and <22.9% for women) were applied based on Korean population reference data [9,20].

This definition has been widely applied in previous KNHANES-based epidemiological studies and is considered appropriate for reflecting body composition in Asian populations [21,22,23]. Body mass index (BMI) was categorized based on the Korean Society for the Study of Obesity recommendations and divided into the following categories: underweight (<18.5 kg/m2), normal weight (18.5 to 22.9 kg/m2), overweight (23.0 to 24.9 kg/m2), and obese (≥25.0 kg/m2) [24].

2.3. Health and Dietary Behavioral Characteristics

Health-related behaviors and clinical variables were assessed using standardized protocols from the KNHANES health interview and examination surveys conducted between 2008 and 2011. Information on health-related behaviors (e.g., smoking, alcohol consumption, and physical activity) was collected via standardized self-reported questionnaires administered by trained interviewers, while clinical measurements (e.g., blood pressure, laboratory values, and physical characteristics of the participants) were obtained through direct physical examinations and laboratory analyses. Alcohol consumption was defined as drinking at least once a month over the past year.

Current smoking status was defined as smoking daily or occasionally during the survey. Physical activity was assessed using the Korean version of the International Physical Activity Questionnaire short form. Based on the World Health Organization (WHO) guidelines on physical activity for health, participants were classified as meeting recommendations if they engaged in ≥150 min per week of moderate-intensity activity or ≥75 min per week of vigorous-intensity activity [25]. Those who did not meet these criteria were categorized into the physically inactive group.

Hypertension (HTN) was identified based on a systolic blood pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90 mmHg. Additionally, participants with a documented physician diagnosis or those undergoing antihypertensive therapy were also included in this category. Diabetes mellitus (DM) was defined as a fasting plasma glucose level ≥ 126 mg/dL, a physician diagnosis, or current treatment for diabetes. Hyperlipidemia was defined as a fasting total cholesterol level ≥ 240 mg/dL, a physician diagnosis, or current use of lipid-lowering medications.

Only participants who had fasted for at least 8 h prior to blood sampling were included for the laboratory-based definition to improve data accuracy. Osteoarthritis (OA) and depression were defined based on physician diagnosis, current treatment, or current disease status. Osteoporosis was defined according to bone mineral density measurements, with a T-score ≤ −2.5 at the total femur, femoral neck, or lumbar spine. We assessed health-related quality of life using the EuroQol-5 Dimension (EQ-5D) index, a standardized tool that encompasses five dimensions [26].

These domains include physical mobility and self-care, as well as the performance of daily activities, the presence of pain or discomfort, and mental health status regarding anxiety or depression [26]. The resulting index score ranges from 0 to 1, with higher values indicating a better health status. We used the Korean-specific valuation set to calculate the final index score [27].

2.4. Statistical Analysis

All statistical analyses were performed using SPSS version 23.0, accounting for the complex survey design of the KNHANES by incorporating sampling weights, strata, and clusters. The resulting weighted estimates are representative of the Korean population and reflect population-level values rather than raw sample data. Continuous variables are expressed as weighted means with 95% confidence intervals (CIs), while categorical variables are presented as weighted proportions. Group comparisons were performed using the complex samples general linear model and the Rao: Scott adjusted chi-square test.

Independent factors associated with sarcopenia were examined using multivariate logistic regression analyses, with variables selected based on clinical relevance and univariate significance. This model further evaluated the association of sex and BMI, adjusting for age and other potential confounders. The results are presented as adjusted odds ratios (ORs) with 95% CIs. Weighted proportions and their 95% CIs were calculated using the Taylor series linearization method within the complex samples module of SPSS. All statistical tests were two-tailed, and a p-value < 0.05 was considered statistically significant.

3. Results

3.1. Comparison of Baseline Characteristics Between the Non-Sarcopenia and Sarcopenia Groups

A total of 238 patients with RA were included in the analysis, of whom 44 (weighted prevalence, 22.7%) were classified as having sarcopenia. Table 1 summarizes the baseline characteristics of the study population according to sarcopenia status. Compared with individuals without sarcopenia, those with sarcopenia were more likely to be male (55.0% vs. 15.3%, p < 0.001) and had significantly higher BMI (26.1 vs. 23.3 kg/m2, p < 0.001) as well as greater waist circumference (86.9 vs. 79.0 cm, p < 0.001).

The prevalence of obesity was also significantly higher among individuals with sarcopenia (54.1% vs. 25.9%, p = 0.003). The two groups showed no remarkable differences in terms of baseline demographics, nutritional parameters (energy and protein), and metabolic indicators (fasting glucose, total cholesterol, and vitamin D). Furthermore, the distribution of comorbidities, such as HTN, hyperlipidemia, OA, osteoporosis, and depression, was comparable between the two groups. Although not statistically significant, a lower proportion of individuals with sarcopenia met the WHO physical activity guidelines compared with those without sarcopenia (73.5% vs. 88.1%, p = 0.070).

3.2. Clinical Predictors of Sarcopenia in Patients with RA

Univariate analyses demonstrated that male sex (OR: 6.79; 95% CI: 2.76 to 16.67, p < 0.001) and obesity (OR: 3.37; 95% CI: 1.51 to 7.53, p = 0.003) were significantly associated with the presence of sarcopenia (Table 2). After adjusting for age, obesity, physical activity, and protein intake, both male sex (OR: 4.17; 95% CI: 1.48 to 11.77, p = 0.007) and obesity (OR: 3.06; 95% CI: 1.16 to 8.07, p = 0.024) persisted as independent predictors of sarcopenia. Meeting the WHO physical activity guideline showed a trend towards association (OR: 0.39; 95% CI: 0.14 to 1.06, p = 0.064), but did not demonstrate a significant effect.

Neither age nor daily protein intake reached statistical significance regarding sarcopenia risk in either the univariate or multivariable analyses.

3.3. Sarcopenia Prevalence and Risk According to BMI Category

Sarcopenia prevalence demonstrated a stepwise increase across BMI categories, rising from 10.1% in the underweight and normal BMI group (<18.5 and 18.5 to 22.9 kg/m2) to 28.0% in the overweight group (23.0 to 24.9 kg/m2) and further to 44.9% in the obese group (≥25.0 kg/m2) (Figure 1). In the multivariable logistic regression analysis adjusted for age and sex, the odds of sarcopenia were significantly higher in overweight (OR: 3.07; 95% CI: 1.02 to 9.22, p < 0.001) and obese (OR: 6.11; 95% CI: 2.06 to 18.12, p < 0.001) groups compared with the underweight and normal BMI group as the reference (Table 3).

These findings support a dose: response association between increasing BMI and the likelihood of sarcopenia.

3.4. Sex-Specific Multivariable Analysis of Risk Factors for Sarcopenia

Sex-stratified multivariable analyses were conducted to examine potential differences in factors associated with sarcopenia between male and female participants (Table 4). In the male patients, not meeting the WHO physical activity guideline was markedly linked to a heightened risk of sarcopenia (OR: 13.00; 95% CI: 1.90 to 88.75, p = 0.012). Additionally, BMI was positively associated with sarcopenia in males (OR: 1.33; 95% CI: 1.05 to 1.68, p = 0.022), although age was not significantly related to sarcopenia (OR: 1.03; 95% CI: 0.99 to 1.08, p = 0.127).

In contrast, among the female patients, only BMI was significantly associated with sarcopenia (OR: 1.35; 95% CI: 1.14 to 1.61, p = 0.001). Age and physical activity did not reach statistical significance in the female group (all p > 0.05). These results suggest that physical activity may influence the risk of sarcopenia differently by sex, although this finding should be interpreted with caution. Due to the limited number of participants in the sex-stratified analyses, particularly among men with sarcopenia, the estimates were associated with wide CIs.

4. Discussion

In this nationally representative cohort from the KNHANES, the weighted prevalence of sarcopenia in patients with RA was about 22.7%. This prevalence is substantially higher than that reported in the general Korean population and underscores the clinical burden of sarcopenia in individuals with RA [28]. Furthermore, our multivariable analyses identified male sex (OR: 4.17; 95% CI: 1.48 to 11.77) and obesity (OR: 3.06; 95% CI: 1.16 to 8.07) as independent risk factors for sarcopenia. The current findings support previous evidence that sarcopenia in RA is associated with sex and obesity [9,29].

In sex-stratified analyses, physical inactivity was significantly associated with sarcopenia only in male patients, whereas BMI remained a significant risk factor in both sexes. Our observations underscore the complex interaction between sex, body composition, and physical activity in RA-related sarcopenia. Furthermore, they underscore the clinical significance of this comorbidity, warranting individualized evaluation and management approaches in susceptible groups.

Several pathophysiological mechanisms can explain the association between RA and sarcopenia. Sarcopenia is a multifactorial condition involving age-related anabolic resistance, chronic inflammation, hormonal changes, physical inactivity, inadequate nutrition, and neuromuscular degeneration [30]. In patients with RA, the persistent release of systemic inflammatory mediators, such as TNF-α, IL-6, and IL-1β, disrupts muscle protein regulation by inhibiting protein synthesis via the insulin-like growth factor-1 (IGF-1)/Akt/mTOR signaling pathway and promoting proteolysis through the ubiquitin: proteasome system [10,31]. Additionally, chronic inflammation causes pain, joint stiffness, and fatigue, which collectively limit physical activity, exacerbate muscle atrophy, and contribute to functional decline [32].

These findings support the central role of inflammation-related molecular and behavioral mechanisms in the pathogenesis of sarcopenia in patients with RA [33]. Moreover, long-term use of glucocorticoids, which are frequently prescribed for the management of RA, may contribute to muscle wasting by increasing protein breakdown and impairing myogenesis. A previous study reported that glucocorticoid use was markedly associated with a higher likelihood of sarcopenia in patients with RA [29]. Therefore, these RA-specific factors establish a chronic catabolic state that promotes the development of sarcopenia.

These mechanisms may partially explain why male sex and excess weight are independently associated with sarcopenia in our analysis. While age-related declines in anabolic hormones like testosterone contribute to muscle loss, male patients in this study showed a significantly higher vulnerability to sarcopenia. This is notable because post-menopausal women experience a more rapid loss of estrogen, suggesting that sex-specific differences in RA involve factors beyond hormonal changes alone. Given that men generally have a greater baseline muscle mass, the catabolic effects of RA-associated chronic inflammation may result in muscle wasting that is more clinically significant than in women.

A previous study also reported that age-related muscle loss progressed more rapidly in men than in women [34,35]. Furthermore, the regulation of muscle protein in response to inflammation differs by sex. Specifically, it has been suggested that the IGF-1/Akt/mTOR axis in men may be more susceptible to inhibition by inflammatory cytokines [36]. In addition to these biological factors, our analysis revealed that physical inactivity was significantly associated with sarcopenia only in male patients. This suggests that lifestyle adjustments in response to RA symptoms, specifically regarding physical activity, may play a critical role in maintaining muscle mass in an inflammatory state.

Thus, the higher prevalence of sarcopenia in men likely results from a combination of greater absolute muscle loss, a higher biological sensitivity to inflammation, and a stronger link between physical inactivity and muscle depletion. These findings suggest that sex-specific hormonal and inflammatory profiles may significantly influence susceptibility to sarcopenia in patients with RA.

Data from this research demonstrated that the prevalence of sarcopenia increased progressively with BMI category, reaching 44.9% among patients with obesity, which suggests a dose: response relationship between increasing adiposity and the risk of muscle loss. While higher body weight is traditionally viewed as a protective mechanical load [37], our findings align with recent clinical observations identifying obesity as an independent risk factor for muscle depletion in RA [28,29]. This clinical discrepancy can be explained by the concept of sarcopenic obesity, which is characterized by the coexistence of excessive adiposity and reduced muscle mass [38].

In this condition, adipose tissue-derived proinflammatory adipokines, such as leptin and IL-6, impair muscle metabolism, while obesity-induced insulin resistance disrupts the anabolic signaling required for muscle protein synthesis [39]. Additionally, obesity-related physical limitations may further reduce the physical activity levels of patients with RA, thereby accelerating muscle loss. This issue is especially critical in Asian populations, including Korean cohorts [40,41]. These individuals often have a lower baseline of muscle mass, which makes them more vulnerable to sarcopenic obesity even at a relatively lower BMI.

Thus, the concurrence of obesity and sarcopenia in RA patients is a critical clinical factor that can significantly worsen disease progression rather than it being a simple coincidence, as reduced muscle mass in these patients can severely impair physical function and increase disability while being masked by excess adiposity. This overlap makes disease management more difficult, as weight-based assessments frequently underestimate the severity of muscle loss. Consequently, identifying sarcopenic obesity in patients with RA may be important for optimizing treatment strategies, including targeted nutritional support and tailored exercise interventions.

Our findings ultimately highlight the need for routine assessments of muscle mass and function in patients with RA, especially among men and those with obesity.

Beyond physical disability, the clinical importance of sarcopenic obesity in RA is closely linked to cardiometabolic comorbidities. The synergistic effect of adiposity and systemic inflammation not only reduces muscle mass but also promotes endothelial dysfunction and cardiovascular disease risk [3]. Sex-specific inflammatory responses further contribute to the cardiovascular risks associated with sarcopenic obesity. For instance, recent research on T2MI reveals that women may be more susceptible to a high inflammatory burden, as it is driven by an imbalance in myocardial oxygen supply and demand rather than acute plaque rupture [4].

Although our findings emphasize the high risk of sarcopenia in men, these observations suggest that the interaction between sex and inflammation in RA affects musculoskeletal and cardiovascular health in distinct ways. Consequently, our results underscore the importance of a comprehensive risk assessment that considers both body composition and sex-specific cardiovascular risks in patients with RA.

The present study has several limitations. First, due to its cross-sectional design, causality between the observed risk factors and sarcopenia cannot be determined. Second, RA diagnoses and comorbidities were based on self-reported physician diagnoses or current treatment status, which may be subject to recall bias. Moreover, although related musculoskeletal conditions (such as OA) are assessed separately in the KNHANES, some degree of misclassification cannot be completely ruled out, potentially influencing the estimated prevalence of sarcopenia. Third, physical activity was assessed using self-reported questionnaires rather than objective measures, which may have affected its accuracy.

Furthermore, a key limitation of this study is the lack of detailed RA-specific clinical variables, such as disease activity, disease duration, serological markers, functional status, and information on pharmacological treatments. These factors are known to influence muscle mass and may contribute to the development of sarcopenia in patients with RA. Therefore, residual confounding cannot be excluded, and the observed associations should be interpreted with caution. Additionally, the sex-stratified analyses are limited by a constrained sample size, particularly men with sarcopenia (n = 18), which may have reduced statistical power and resulted in wide confidence intervals.

Consequently, these findings should be interpreted as preliminary rather than definitive. Future studies incorporating detailed clinical data are needed to better elucidate these relationships. However, an important strength of this study is the use of a large, nationally representative dataset to examine weight-adjusted ASM criteria for sarcopenia in the Korean population.

5. Conclusions

In conclusion, our findings emphasize the substantial burden of sarcopenia among patients with RA, and identify male sex and obesity as important risk factors. Clinicians should consider routine assessments of muscle mass and function in RA management, especially in high-risk individuals. Future research using longitudinal data is warranted to clarify the causal mechanisms and evaluate interventions aimed at preventing sarcopenia in this patient population.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

C.-N.S. and Y.-J.O. made substantial contributions to the conception and design of the work and the interpretation of the data. C.-N.S. and Y.-J.O. led the acquisition of the data, and Y.-J.O. led the analysis of the data. C.-N.S. and Y.-J.O. drafted the work and reviewed it critically for important intellectual content and approved the final manuscript version for publication. C.-N.S. and Y.-J.O. agreed to be accountable for all aspects of the work. C.-N.S. is responsible for the overall content as guarantor.

All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Ethical committee approval was received from the Ethics Committee of Uijeongbu Eulji Medical Center (Approval no: UEMC 2025-08-002-001, Date: 5 September 2025).

Informed Consent Statement

Informed consent was obtained from all participants by the Korea Disease Control and Prevention Agency (KDCA) at the time of the KNHANES survey. Since this study analyzed anonymized secondary data, additional informed consent was not required.

Data Availability Statement

Data are available in a public repository. The datasets used in this study are available from the Korea National Health and Nutrition Examination Survey (KNHANES) website (https://knhanes.kdca.go.kr/knhanes/, accessed on 20 April 2026).

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Jahid M. Khan K.U. Rehan Ul H. Ahmed R.S. Overview of rheumatoid arthritis and scientific understanding of the disease Mediterr. J. Rheumatol. 2023 34 284 291 10.31138/mjr.20230801.oo 37941854 PMC10628871
2. Figus F.A. Piga M. Azzolin I. McConnell R. Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities Autoimmun. Rev. 2021 20 102776 10.1016/j.autrev.2021.102776 33609792
3. Sattar N. McCarey D.W. Capell H. McInnes I.B. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis Circulation 2003 108 2957 2963 10.1161/01.CIR.0000099844.31524.05 14676136
4. Angeli F. Bucciarelli V. Moscucci F. Sciomer S. Ricci F. Coppi F. Bergamaschi L. Armillotta M. Casuso Alvarez M. Renda G. Gender and sex-related differences in type 2 myocardial infarction: The undervalued side of a neglected disease Trends Cardiovasc. Med. 2026 36 27 34 10.1016/j.tcm.2025.07.007 40701444
5. Li T.H. Chang Y.S. Liu C.W. Su C.F. Tsai H.C. Tsao Y.P. Liao H.T. Chen M.H. Chuang C.C. Yang Y.Y. The prevalence and risk factors of sarcopenia in rheumatoid arthritis patients: A systematic review and meta-regression analysis Semin. Arthritis Rheum. 2021 51 236 245 10.1016/j.semarthrit.2020.10.002 33385864
6. An H.J. Tizaoui K. Terrazzino S. Cargnin S. Lee K.H. Nam S.W. Kim J.S. Yang J.W. Lee J.Y. Smith L. Sarcopenia in autoimmune and rheumatic diseases: A comprehensive review Int. J. Mol. Sci. 2020 21 5678 10.3390/ijms21165678 32784808 PMC7461030
7. Moschou D. Krikelis M. Georgakopoulos C. Mole E. Chronopoulos E. Tournis S. Mavragani C. Makris K. Dontas I. Gazi S. Sarcopenia in rheumatoid arthritis. A narrative review J. Frailty Sarcopenia Falls 2023 8 44 52 10.22540/JFSF-08-044 36873824 PMC9975974
8. Yuan S. Larsson S.C. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences Metabolism 2023 144 155533 10.1016/j.metabol.2023.155533 36907247
9. Kim D. Lee Y.J. Song E.S. Kim A. Bang C.H. Jung J.H. The high prevalence of sarcopenia in rheumatoid arthritis in the korean population: A nationwide cross-sectional study Healthcare 2023 11 1401 10.3390/healthcare11101401 37239687 PMC10218272
10. Bennett J.L. Pratt A.G. Dodds R. Sayer A.A. Isaacs J.D. Rheumatoid sarcopenia: Loss of skeletal muscle strength and mass in rheumatoid arthritis Nat. Rev. Rheumatol. 2023 19 239 251 10.1038/s41584-023-00921-9 36801919
11. Liguori I. Russo G. Aran L. Bulli G. Curcio F. Della-Morte D. Gargiulo G. Testa G. Cacciatore F. Bonaduce D. Sarcopenia: Assessment of disease burden and strategies to improve outcomes Clin. Interv. Aging 2018 13 913 927 10.2147/CIA.S149232 29785098 PMC5957062
12. Dalle S. Rossmeislova L. Koppo K. The role of inflammation in age-related sarcopenia Front. Physiol. 2017 8 1045 10.3389/fphys.2017.01045 29311975 PMC5733049
13. Kitamura A. Seino S. Abe T. Nofuji Y. Yokoyama Y. Amano H. Nishi M. Taniguchi Y. Narita M. Fujiwara Y. Sarcopenia: Prevalence, associated factors, and the risk of mortality and disability in japanese older adults J. Cachexia Sarcopenia Muscle 2021 12 30 38 10.1002/jcsm.12651 33241660 PMC7890144
14. Bano G. Trevisan C. Carraro S. Solmi M. Luchini C. Stubbs B. Manzato E. Sergi G. Veronese N. Inflammation and sarcopenia: A systematic review and meta-analysis Maturitas 2017 96 10 15 10.1016/j.maturitas.2016.11.006 28041587
15. Cano-García L. Manrique-Arija S. Domínguez-Quesada C. Vacas-Pérez J.C. Armenteros-Ortiz P.J. Ruiz-Vilchez D. Martín-Martín J.M. Redondo-Rodríguez R. García-Studer A. Ortiz-Márquez F. Sarcopenia and nutrition in elderly rheumatoid arthritis patients: A cross-sectional study to determine prevalence and risk factors Nutrients 2023 15 2440 10.3390/nu15112440 37299407 PMC10255254
16. Dietzel R. Wiegmann S. Borucki D. Detzer C. Zeiner K.N. Schaumburg D. Buehring B. Buttgereit F. Armbrecht G. Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised ewgsop2 and the fnih definition RMD Open 2022 8 e002600 10.1136/rmdopen-2022-002600 36180102 PMC9528715
17. Kweon S. Kim Y. Jang M.J. Kim Y. Kim K. Choi S. Chun C. Khang Y.H. Oh K. Data resource profile: The korea national health and nutrition examination survey (knhanes) Int. J. Epidemiol. 2014 43 69 77 10.1093/ije/dyt228 24585853 PMC3937975
18. Lee S.Y. Ahn S. Kim Y.J. Ji M.J. Kim K.M. Choi S.H. Jang H.C. Lim S. Comparison between dual-energy x-ray absorptiometry and bioelectrical impedance analyses for accuracy in measuring whole body muscle mass and appendicular skeletal muscle mass Nutrients 2018 10 738 10.3390/nu10060738 29880741 PMC6024648
19. Heymsfield S.B. Smith R. Aulet M. Bensen B. Lichtman S. Wang J. Pierson R.N. Jr. Appendicular skeletal muscle mass: Measurement by dual-photon absorptiometry Am. J. Clin. Nutr. 1990 52 214 218 10.1093/ajcn/52.2.214 2375286
20. Hwang B. Lim J.Y. Lee J. Choi N.K. Ahn Y.O. Park B.J. Prevalence rate and associated factors of sarcopenic obesity in korean elderly population J. Korean Med. Sci. 2012 27 748 755 10.3346/jkms.2012.27.7.748 22787369 PMC3390722
21. Han E. Lee Y.H. Kim G. Kim S.R. Lee B.W. Kang E.S. Ahn C.W. Cha B.S. Sarcopenia is associated with albuminuria independently of hypertension and diabetes: Knhanes 2008 to 2011 Metabolism 2016 65 1531 1540 10.1016/j.metabol.2016.07.003 27621188
22. Kim Y.S. Lee Y. Chung Y.S. Lee D.J. Joo N.S. Hong D. Song G. Kim H.J. Choi Y.J. Kim K.M. Prevalence of sarcopenia and sarcopenic obesity in the korean population based on the fourth korean national health and nutritional examination surveys J. Gerontol. A Biol. Sci. Med. Sci. 2012 67 1107 1113 10.1093/gerona/gls071 22431554
23. Hong K.S. Kim M.C. Ahn J.H. Sarcopenia is an independent risk factor for nafld in copd: A nationwide survey (knhanes 2008 to 2011) Int. J. Chronic Obstr. Pulm. Dis. 2020 15 1005 1014 10.2147/COPD.S249534 32440112 PMC7213902
24. Kim K.K. Haam J.H. Kim B.T. Kim E.M. Park J.H. Rhee S.Y. Jeon E. Kang E. Nam G.E. Koo H.Y. Evaluation and treatment of obesity and its comorbidities: 2022 update of clinical practice guidelines for obesity by the korean society for the study of obesity J. Obes. Metab. Syndr. 2023 32 1 24 10.7570/jomes23016 36945077 PMC10088549
25. Bull F.C. Al-Ansari S.S. Biddle S. Borodulin K. Buman M.P. Cardon G. Carty C. Chaput J.P. Chastin S. Chou R. World health organization 2020 guidelines on physical activity and sedentary behaviour Br. J. Sports Med. 2020 54 1451 1462 10.1136/bjsports-2020-102955 33239350 PMC7719906
26. Brooks R. Euroqol: The current state of play Health Policy 1996 37 53 72 10.1016/0168-8510(96)00822-6 10158943
27. Lee Y.K. Nam H.S. Chuang L.H. Kim K.Y. Yang H.K. Kwon I.S. Kind P. Kweon S.S. Kim Y.T. South korean time trade-off values for eq-5d health states: Modeling with observed values for 101 health states Value Health 2009 12 1187 1193 10.1111/j.1524-4733.2009.00579.x 19659703
28. Giles J.T. Ling S.M. Ferrucci L. Bartlett S.J. Andersen R.E. Towns M. Muller D. Fontaine K.R. Bathon J.M. Abnormal body composition phenotypes in older rheumatoid arthritis patients: Association with disease characteristics and pharmacotherapies Arthritis Rheum. 2008 59 807 815 10.1002/art.23719 18512711 PMC2670994
29. Vlietstra L. Stebbings S. Meredith-Jones K. Abbott J.H. Treharne G.J. Waters D.L. Sarcopenia in osteoarthritis and rheumatoid arthritis: The association with self-reported fatigue, physical function and obesity PLoS ONE 2019 14 e0217462 10.1371/journal.pone.0217462 31170172 PMC6553728
30. Cruz-Jentoft A.J. Sayer A.A. Sarcopenia Lancet 2019 393 2636 2646 10.1016/S0140-6736(19)31138-9 31171417
31. Reid M.B. Moylan J.S. Beyond atrophy: Redox mechanisms of muscle dysfunction in chronic inflammatory disease J. Physiol. 2011 589 2171 2179 10.1113/jphysiol.2010.203356 21320886 PMC3098696
32. Pan J. Zou Y.W. Zhu Y.Y. Lin J.Z. Wu T. Yang Z.H. Zhang X.P. Zhang Q. Zheng H.W. He X.L. Muscle mass loss is associated with physical dysfunction in patients with early rheumatoid arthritis Front. Nutr. 2022 9 1007184 10.3389/fnut.2022.1007184 36505248 PMC9727302
33. Pérez-Baos S. Prieto-Potin I. Román-Blas J.A. Sánchez-Pernaute O. Largo R. Herrero-Beaumont G. Mediators and patterns of muscle loss in chronic systemic inflammation Front. Physiol. 2018 9 409 10.3389/fphys.2018.00409 29740336 PMC5928215
34. Smith G.I. Mittendorfer B. Sexual dimorphism in skeletal muscle protein turnover J. Appl. Physiol. 2016 120 674 682 10.1152/japplphysiol.00625.2015 26702024 PMC4796180
35. Mitchell W.K. Williams J. Atherton P. Larvin M. Lund J. Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review Front. Physiol. 2012 3 260 10.3389/fphys.2012.00260 22934016 PMC3429036
36. Erfurth E.M. Hagmar L.E. Sääf M. Hall K. Serum levels of insulin-like growth factor i and insulin-like growth factor-binding protein 1 correlate with serum free testosterone and sex hormone binding globulin levels in healthy young and middle-aged men Clin. Endocrinol. 1996 44 659 664 10.1046/j.1365-2265.1996.731552.x 8801037
37. Felson D.T. Zhang Y. Hannan M.T. Anderson J.J. Effects of weight and body mass index on bone mineral density in men and women: The framingham study J. Bone Miner. Res. 1993 8 567 573 10.1002/jbmr.5650080507 8511983
38. Nezameddin R. Itani L. Kreidieh D. El Masri D. Tannir H. El Ghoch M. Understanding sarcopenic obesity in terms of definition and health consequences: A clinical review Curr. Diabetes Rev. 2020 16 957 961 10.2174/1573399816666200109091449 31916519
39. Hotamisligil G.S. Arner P. Caro J.F. Atkinson R.L. Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance J. Clin. Investig. 1995 95 2409 2415 10.1172/JCI117936 7738205 PMC295872
40. Lee D.Y. The prevalence of and factors associated with sarcopenic obesity, sarcopenia, and obesity among korean adults: Findings from the 2022 to 2023 korea national health and nutrition examination survey Medicina 2025 61 1424 10.3390/medicina61081424 40870469 PMC12388213
41. Park J.E. Lee S. Kim K. The effect of combining nutrient intake and physical activity levels on central obesity, sarcopenia, and sarcopenic obesity: A population-based cross-sectional study in south korea BMC Geriatr. 2023 23 119 10.1186/s12877-023-03748-x 36869315 PMC9985216
Figure 1

Prevalence of sarcopenia according to BMI categories in patients with RA.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Baseline characteristics of study participants according to sarcopenia status.

VariablesNon-Sarcopenia (n = 194)Sarcopenia (n = 44)p Value
Age, years56.0 (53.4 to 58.6)52.2 (45.4 to 59.0)0.279
Male, %15.3 (9.7 to 23.2)55.0 (37.0 to 71.8)<0.001
BMI, kg/m223.3 (22.8 to 23.8)26.1 (24.9 to 27.2)<0.001
Waist circumference (cm)79.0 (77.5 to 80.5)86.9 (84.2 to 89.6)<0.001
Current smoker, %60.6 (43.5 to 75.5)66.2 (45.8 to 82.0)0.662
Current drinker, %39.0 (30.7 to 48.0)51.9 (33.7 to 69.6)0.212
Obesity, %25.9 (19.6 to 33.3)54.1 (35.9 to 71.2)0.003
Meets WHO physical activity guideline88.1 (81.3 to 92.7)73.5 (51.5 to 87.8)0.070
EQ-5D index0.9 (0.8 to 0.9)0.8 (0.7 to 0.9)0.448
Intake energy, g/day1665.8 (1524.5 to 1807.0)1642.4 (1408.7 to 1876.2)0.868
Protein, g/kg/day57.7 (51.4 to 64.1)58.5 (45.7 to 71.3)0.920
Fasting glucose96.3 (91.5 to 101.2)106.2 (86.8 to 125.6)0.337
Total cholesterol189.0 (183.5 to 194.6)189.5 (173.4 to 205.6)0.958
25 (OH) Vitamin D18.5 (16.8 to 20.2)17.3 (15.1 to 19.6)0.401
Comorbidities, %
Hypertension28.0 (21.4 to 35.8)24.3 (11.7 to 43.8)0.680
Hyperlipidemia14.1 (9.5 to 20.5)20.2 (8.5 to 40.7)0.428
Osteoarthritis23.4 (16.6 to 31.8)13.4 (5.5 to 29.1)0.161
Osteoporosis36.6 (28.6 to 45.5)21.9 (9.9 to 41.8)0.131
MDD15.7 (10.2 to 23.4)14.3 (5.2 to 33.6)0.833

Values are presented as weighted means (95% confidence intervals) for continuous variables and as weighted percentages (95% confidence intervals) for categorical variables. p-values were calculated using a complex sample general linear model, accounting for sample weights, strata, and clusters. n represents an unweighted sample. All estimates are weighted to represent the Korean population. WHO, World Health Organization; MDD, major depressive disorder; EQ-5D, EuroQol-5-Dimension.

Table 2

Logistic regression analysis of factors associated with sarcopenia in patients with RA.

VariablesUnivariateMultivariate
OR (95% CI)p ValueOR (95% CI)p Value
Male6.79 (2.76 to 16.67)<0.0014.17 (1.48 to 11.77)0.007
Age0.98 (0.96 to 1.01)0.2561.00 (0.96 to 1.03)0.781
Obesity3.37 (1.51 to 7.53)0.0033.06 (1.16 to 8.07)0.024
Meets WHO physical activity guideline0.37 (0.13 to 1.12)0.0780.39 (0.14 to 1.06)0.064
Daily protein intake1.00 (0.99 to 1.01)0.9191.00 (0.98 to 1.01)0.597

Values are presented as weighted odds ratios (ORs) with 95% confidence intervals (CIs) for univariate and multivariate logistic regression models. Multivariate analysis included adjustments for age, sex, obesity, physical activity, and daily protein intake, along with sample weights, strata, and clusters based on a complex survey design. WHO, World Health Organization.

Table 3

Sarcopenia prevalence and odds ratios according to BMI category in patients with RA.

BMI Category (kg/m2)Weighted NWeighted Sarcopenia NWeighted Prevalence (%) OR
(95% CI)
p Value
Underweight and Normal BMI
(<18.5 and 18.5 to 22.9, respectively)
48,964,6414,929,49910.11.00 (Reference)
Overweight
(23.0 to 24.9)
18,109,7205,072,29528.03.07 (1.02 to 9.22)<0.001
Obese (≥25.0)24,395,84010,947,70444.96.11 (2.06 to 18.12)<0.001

N and the percentages are weighted estimates that account for the complex survey design. BMI, body mass index; OR, odds ratio; CI, confidence interval. Weighted proportions may not sum to 100% due to rounding and the application of sampling weights. p-values were calculated using the underweight and normal BMI group as the reference.

Table 4

Multivariable logistic regression analysis of factors associated with sarcopenia in male and female patients with RA.

VariablesMale OR (95% CI), pFemale OR (95% CI), p
Age1.03 (0.99 to 1.08), p = 0.1271.00 (0.96 to 1.03), p = 0.786
BMI1.33 (1.05 to 1.68), p = 0.0221.35 (1.14 to 1.61), p = 0.001
Not meeting WHO physical activity guideline13.00 (1.90 to 88.75), p = 0.0120.59 (0.12 to 3.01), p = 0.520

Values are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Separate multivariate logistic regression models were fitted for male and female patients, adjusting for age, body mass index (BMI), and adherence to the World Health Organization (WHO) physical activity guidelines. The analyses used a complex survey design that included sampling weights, strata, and clusters. The number of participants included in the sex-stratified analyses was 45 for men (18 with sarcopenia and 27 without) and 193 for women (26 with sarcopenia and 167 without).

Publication and source details

Original title: Male Sex and Obesity are Associated with Sarcopenia in Patients with Rheumatoid Arthritis in the 2008 to 2011 Korea National Health and Nutrition Examination Survey

Yoon-Jeong Oh; Chang-Nam Son

Journal of Clinical Medicine · 2026

* Correspondence: cnson@eulji.ac.kr; Tel.: +82-10-9924-1938© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Eulji Universityhttps://ror.org/005bty106 EJRG-24-12This study was supported by Eulji University in 2024 (EJRG-24-12).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:23:43.049047+00:00

DOI: 10.3390/jcm15083148 · PMC13117649